Beijing has sought to take on more responsibility within United Nations agencies as the United States under President Donald Trump winds down its engagement

Overview Debates Related claims Topics Sources

Tensions within the Make America Healthy Again movement increased after President Donald Trump issued an executive order in February 2026 to increase domestic production of the weed killer glyphosate

President Donald Trump nominated wellness influencer Dr. Casey Means for surgeon general, but her nomination was withdrawn after Senate confirmation stalled over concerns regarding her medical experience and vaccine stances

In an October 22, 2026 statement announcing his resignation, Calley Means, a senior adviser to Health and Human Services Secretary Robert F. Kennedy Jr., expressed tremendous respect for President Donald Trump and Kennedy without stating a reason

Grassroots Make America Healthy Again activists and figures expressed discontent with the Trump administration's slow progress on regulating ultraprocessed foods and pesticides like glyphosate

The Wall Street Journal first reported Calley Means' resignation from his White House advisory post ahead of the 2026 midterm elections

Prior to joining the Trump administration as an adviser to Robert F. Kennedy Jr., Calley Means was the founder of Truemed and co-authored the 2024 book "Good Energy" with his sister Casey Means

The U.S. Treasury Department proposed adding biotechnology to the COINS Act list of sensitive restricted industries, alongside semiconductors, artificial intelligence, and quantum computing

Western pharmaceutical companies have invested tens of billions of dollars in Chinese biotechnology companies and licensing agreements to bolster their drug development pipelines

The U.S. Treasury Department cited national security concerns that American investments in Chinese biotech could be used to create biological weapons, develop brain-computer interfaces for surveillance, or cause U.S. supply chain overdependence

On October 22, 2026, the U.S. Treasury Department proposed updated rules for implementing the Comprehensive Outbound Investment National Security (COINS) Act of 2025 to restrict U.S. investment in the Chinese biotechnology sector

The U.S. Treasury Department's proposed COINS Act regulations would require U.S. investors to notify the government regarding certain biotech transactions in China and prohibit others entirely, subjecting violators to civil penalties and divestment

The U.S. Treasury Department's proposed restrictions cover equity interest acquisitions, debt financing, joint ventures, brain-computer interfaces, biomanufacturing equipment, and life sciences tools involving Chinese entities

The U.S. Treasury Department proposal defines prohibited biotech technologies to include small molecules, polymers, vaccines, blood components, allergenics, cell and gene therapies, and monoclonal antibodies or other recombinant therapeutic proteins

China halted poultry imports from Rio Grande do Sul following a 2024 Newcastle disease detection before lifting the restriction earlier in 2026

Meat industry group ABPA stated that the Brazil-China trade protocol triggers an auto-embargo on poultry shipments following a Newcastle disease outbreak before Chinese authorities decide whether restrictions apply to an entire state or limited farm area

In June 2026, Sciwind Biosciences reported Phase 2 SLIMMER-UP-SWITCH trial data from China showing subcutaneous ecnoglutide achieved 12.8% weight loss versus 9.5% for semaglutide at 20 weeks, 35% greater (163 patients).

Prior to taking office, Health Secretary Robert F. Kennedy Jr. declared that the Food and Drug Administration's opposition to peptides and wellness products would end

Health Secretary Robert F. Kennedy Jr. stated that US compounding pharmacies should be permitted to make peptides to prevent consumers from purchasing gray-market products manufactured in China

Health and Human Services Secretary Robert F. Kennedy Jr. directed the Food and Drug Administration earlier in 2026 to reconsider restrictions on peptides such as BPC-157 that are widely promoted by wellness influencers

On October 14, 2026, the Trump administration removed Affordable Care Act marketplace subsidies for approximately 189,000 enrollees after CMS identified roughly 120,000 Medicaid, 58,000 Medicare, and about 11,000 deceased duplicate cases through July 2026